Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop

cryptocurrency 10 hours ago
Flipboard
Cassava Sciences is ending simufilam development for Alzheimer's after Phase 3 trials failed. The company is shifting focus to potential seizure …
Read Entire Article